March 28, 2026
RA Jainee
SBI Healthcare Opportunities Fund
| Fund at a Glance | |
| NAV Growth (Rs.) | 481.04 |
| NAV Bonus (Rs.) | — |
| NAV IDCW (Rs.) | 334.21 |
| Min. Investment (Rs.) | 5,000 |
| Min. SIP Investment (Rs.) | 500 |
| Min. No of Cheques | 12 |
| Benchmark | BSE Healthcare TRI |
| AUM Rs. | 4,077 Cr |
| (As on 28-Feb-2026) | |
| Expense | 0.91% |
| 1 Year Return (%) | 6.15 |
| 3 Year Return (%) | 25.72 |
| 5 Year Return (%) | 17.79 |
| 10 Year Return (%) | 12.96 |
| Return Since Launch | 16.98% |
⚖️ Sahifund Review – SBI Healthcare Opportunities Fund ✔
PLUS: Stability, track record, cost efficiency
SBI Healthcare Opportunities Fund has built a strong long-term track record, delivering nearly 26% CAGR over 3 years and close to 18% over 5 years, which is impressive for a sectoral fund. It has also outperformed its benchmark over 5-year, 7-year and 10-year periods, showing solid wealth creation over time. The fund follows a relatively stable strategy with low turnover of just 18%, which adds comfort in a volatile healthcare theme. Its portfolio has a balanced mix of large, mid and small-cap healthcare names, helping diversify within the sector. Backed by the strong research ecosystem of SBI Mutual Fund, the scheme carries fund house credibility and long-term category relevance. For investors seeking exposure to India’s structural healthcare, pharma and diagnostics growth, this can work as a satellite SIP allocation.
MINUS: Large AUM, large-cap bias, momentum lag
The biggest concern is the fund’s weak recent momentum, with 1-year return of 6.15%, which lags both the benchmark and many peers. It also trails category leaders like ICICI Prudential Pharma Healthcare & Diagnostics on key performance metrics. Being a sectoral fund, it comes with very high concentration risk, as nearly 97% of the portfolio is in top 3 healthcare-related sectors. The portfolio also appears expensively valued, with P/E above 50 and P/B above 6, leaving less room for valuation comfort. Despite reasonable diversification across stocks, the fund remains exposed to policy changes, USFDA issues, pricing pressure and regulatory risk, which can sharply affect returns. This makes it unsuitable as a core holding and appropriate only for investors who can tolerate high thematic volatility.
Sahifund View (Decisive Line):
A strong long-term healthcare theme fund, but due to sector concentration and weak recent momentum, it is best suited as a small SIP-based satellite allocation, not a portfolio core.
👉 Apply Online | Ask Us MF Queries |
| NFO Guidance |
What lies ahead? Below we decode returns consistency, portfolio concentration, peer positioning and risk profile in detail.
Suitable For Which Investors?
Nobody should invest in Pharma funds in our opinion, because:
• They have a narrow focus on only pharmaceutical and healthcare companies
• Instead, diversified equity funds which invest across sectors are better
If you still choose to invest:
1. Invest only through SIP
2. Have a 7+ year investment horizon
3. Be prepared to withstand interim sharp declines in investment value
Fund’s Investment Strategy:
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Fund Manager:
1) Tanmaya Desai
Education: Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).
Experience: Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.
Investment Details
| Min. Investment (Rs) | 5,000 |
| Min. Addl Investment (Rs) | 1,000 |
| Min. SIP Investment (Rs) | 500 |
| Min. Withdrawal (Rs) | 500 |
| Min. No of Cheques | 12 |
| Min. Balance (Rs) | 1,000 |
| Lock-in Period | NA |
| Exit Load | 0.5% for redemption within 15 days |
Basic Details of SBI Healthcare Opportunities Fund
| Fund House | SBI Mutual Fund |
| Launch Date | 01-Jan-13 |
| Return Since Launch | 16.98% |
| Benchmark | BSE Healthcare TRI |
| Riskometer | Very High |
| Type | Open-ended |
| Assets (Rs.) | 4,077 Cr |
| (As on 28-Feb-2026) | |
| Expense | 0.91% |
| (As on 28-Feb-2026) | |
| Risk Grade | Below Average |
| Return Grade | Above Average |
| Turnover | 18.00% |
Trailing Returns (%)
| Fund name | YTD | 1D | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y |
| SBI Healthcare Opportunities Dir | -1.41 | -0.64 | -1.10 | -1.56 | -4.10 | 6.15 | 25.72 | 17.79 | 20.82 | 12.96 |
| BSE Healthcare TRI | -3.27 | -1.13 | -1.53 | -3.12 | -5.35 | 8.18 | 25.79 | 15.61 | 17.59 | 11.20 |
| Equity: Sectoral-Pharma | -2.80 | -0.94 | -1.42 | -2.52 | -4.34 | 8.74 | 24.38 | 15.94 | 20.33 | 13.59 |
| Rank within category | 8 | 4 | 7 | 10 | 11 | 18 | 4 | 1 | 4 | 4 |
| Number of funds in category | 24 | 25 | 24 | 24 | 23 | 21 | 12 | 10 | 8 | 4 |
Peer Comparison of SBI Healthcare Opportunities Fund
| Rating | 1 Year Returns | 3 Year Returns | 5 Year Returns | Expense Ratio (%) | Net Assets (Rs Cr) | Return Since Launch (%) | Exit Load (Days) | Fund Age | Turnover (%) | |
| SBI Healthcare Opportunities Dir | 4 star | 6.15 | 25.72 | 17.79 | 0.91 | 4,077 | 16.98 | 0.50 (15) | 13Y 2M | 18.00 |
| ICICI Pru Pharma Healthcare and Diagnostics Dir | 5 star | 7.88 | 27.92 | 17.69 | 1.04 | 6,801 | 19.91 | 1.00 (15) | 7Y 8M | 55.00 |
| UTI Healthcare Dir | 4 star | 8.43 | 26.00 | 15.88 | 1.29 | 1,107 | 15.26 | 1.00 (30) | 13Y 2M | 33.00 |
| Nippon India Pharma Dir | 3 star | 8.35 | 24.08 | 15.94 | 0.91 | 8,306 | 17.05 | 1.00 (30) | 13Y 2M | 15.00 |
| DSP Healthcare Dir | 3 star | 1.77 | 22.43 | 15.26 | 0.65 | 3,033 | 21.11 | 0.50 (30) | 7Y 3M | 4.00 |
Portfolio Analysis of SBI Healthcare Opportunities Fund
| No. of Stocks | 32 |
| Top 10 Stocks | 52.95% |
| Top 5 Stocks | 33.55% |
| Top 3 Sectors | 97.00% |
| Portfolio P/B Ratio | 6.22 |
| Portfolio P/E Ratio | 50.57 |
Portfolio Breakup
| Fund | Category | |
| Average Mkt Cap (Rs Cr) | 61,554 | 80,098 |
| Giant (%) | — | — |
| Large (%) | 35.17 | 42.52 |
| Mid (%) | 26.54 | 31.81 |
| Small (%) | 38.29 | 28.41 |
| Tiny (%) | — | — |
Disclaimer: Mutual fund investments are subject to market risks. Read all scheme related documents carefully
Quicklinks
- Chanakyanipothi.com
- Staffavailable.com
- BigGaddi.com
- Latest IPO GMP
- Best Stocks to buy today
- Grey Market Premium
- Upcoming IPOs
- Subscription Status